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Work of breathing, not dysoxia, as the
cause of low central venous blood O2
saturation in sepsis
Guillermo Gutierrez
The review by Nguyen et al. [1] acknowledges the sub-
stantially lower baseline central venous oxygen satur-
ation (ScvO2) values reported by Rivers et al. [2] (48.6 ±
11.2 %) when compared to those for ProCESS [3] (71 ±
13 %), ARISE [4] (72.7 ± 10.5 %) and ProMISe [5] (64 ±
20 %) trials. Assuming normality, the distribution of
baseline ScvO2 values in the study by Rivers et al. dif-
fered from those of the other trials (Fig. 1; p < 0.0001 by
t test). Nguyen et al. ascribed this difference to “earlier
central venous catheter (CVC) placement, greater shock
severity or imbalances between O2 delivery and O2 con-
sumption before corrective interventions”.
One aspect of these trials that has been ignored up to
now is the CVC position in the superior vena cava. Ac-
cording to accepted guidelines, the tip of the CVC
should lie below the anterior first rib and above the right
atrium, placing the tip of the CVC below the opening of
the azygos vein, a vessel carrying venous blood from the
intercostal muscles and portions of the diaphragm.
In the study by Rivers et al., 53.8 % of patients random-
ized to the early goal-directed therapy (EGDT) group re-
quired invasive mechanical ventilation during the first 6 h
of treatment, a greater rate (p < 0.0001; Chi Square test)
than those reported by ProCESS (26.4 %), ARISE (22.2 %),
and ProMISe (19 %). Furthermore, the baseline respiratory
rate for the EGDT cohort in Rivers et al. (31.8 ± 10.8 bpm)
was greater (p < 0.001) than those reported by ProCESS
(25.4 ± 7.0 bpm) and ARISE (24. ± 7.5 bpm). The baseline
respiratory rate for patients in the ProMISe trial was not
reported.
These data infer that patients in the study of Rivers et
al. experienced considerable respiratory distress prior to
the initiation of mechanical ventilation. This condition
was likely associated with an increased work of breath-
ing and the discharge of highly desaturated blood by the
azygos vein into the superior vena cava, in close proxim-
ity to the fiber optic lumen of the catheter tip, precisely
where ScvO2 was measured spectrophotometrically.
It is reasonable, therefore, to propose that the low ScvO2
values reported in the study of Rivers et al. reflected work
by the muscles of respiration and not sepsis-associated
systemic tissue dysoxia. In that instance, the ScvO2
increases observed during the first 6 h of treatment in the
study by Rivers et al. may have been in response to
unloading of respiratory muscles by mechanical ventila-
tion and not to red blood cell transfusion or dobutamine
infusion as proposed by their treatment algorithm.
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Fig. 1 Gaussian distributions for baseline SCVO2 reported by Rivers et
al [2], ProCESS [3], ARISE [4] and ProMISe trials [5]. Baseline SCVO2
was substantially lower in the Rivers et al trial when compared to
each of the other trials (p < 0.0001)
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